Emerging treatments
Antithymocyte globulin and hematopoietic stem cell transplant
Antithymocyte globulin is usually used for acute transplant rejection. It is a polyclonal antibody that depletes CD4 lymphocytes by binding to surface antigens. Preliminary data from small studies indicate benefit of autologous nonmyeloablative hematopoietic stem cell transplant and antithymocyte globulin in refractory systemic vasculitis.[71][72]
Alemtuzumab
Identifying molecular targets in nonsystemic vasculitic neuropathy is an active area of research. One study showed that CD52 is found in nerve biopsies of patients with nonsystemic vasculitic neuropathy.[73] Therefore, alemtuzumab, an anti-CD52 monoclonal antibody, may be a potential pharmacologic therapy for nonsystemic vasculitic neuropathy.
Use of this content is subject to our disclaimer